HHS lets compounding pharmacies offer six peptides the FDA has not approved

HHS will not penalize pharmacies that compound six unapproved peptides, overriding objections from FDA scientists.

Objective Facts

The Department of Health and Human Services posted an interim policy on Oct. 28, 2026, saying it will not act against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides the FDA has not approved: BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax. AJMC reported that Health Secretary Robert F. Kennedy Jr. signed the policy through his own office, and the Associated Press reported that most FDA scientific staff opposed it. CBS News said the policy requires patient-specific prescriptions, traceable ingredients, quality testing and adverse event reporting, and an HHS spokesperson told CBS it "does not grant FDA approval or establish clinical safety and effectiveness." The policy stays in place until the FDA finalizes a rule on its compounding bulks list, which the agency has not yet proposed, and public comment runs through Nov. 13.

Left-Leaning Perspective

Mainstream left-leaning coverage stressed that Kennedy went around his own scientists and that the evidence for these peptides is thin. ABC News's Youri Benadjaoud reported that no published clinical trials show the six peptides work in humans for any condition. CBS News, in a piece by Dr. Jon LaPook and Faris Tanyos, paired the policy with its own test of a bodega peptide sample that contained no peptide at all. Futurism's Maggie Harrison Dupré framed the move as opening the floodgates and quoted former FDA chief Janet Woodcock warning that it erodes the principle of testing drugs before wide use.

Right-Leaning Perspective

The right-of-center coverage we found came from libertarian outlets, which largely backed the move. Reason senior editor Elizabeth Nolan Brown called the policy a win for health freedom, argued that pharmacy-made peptides are safer than gray market imports and said the safeguards are reasonable, while noting the policy is a backdoor around an FDA that has not decided. Jeffrey A. Singer of the Reason Foundation, writing two days before the release, argued that adults should be free to accept uncertain risks and that blocking accountable suppliers pushes buyers to worse sources. We did not find opinion coverage of the final policy from The Wall Street Journal, National Review or Fox News.

Deep Dive

The policy grows out of a two-year fight. In 2023 the FDA placed BPC-157, TB-500 and other peptides on a list of substances that should not be compounded, citing risks such as immune reactions, according to the AP. Kennedy, who has called himself a "big fan" of peptides according to the AP, reshaped the FDA's compounding advisory panel, which in July voted to recommend six of seven peptides under review. AJMC reported that HHS then issued enforcement discretion through the Secretary's office after FDA staff resisted writing a rule declaring the products safe. Critics are on firm ground about the evidence: ABC News reported no published human trials show these peptides work for any condition, and FDA scientists flagged possible liver damage and allergic reactions, according to KFF Health News. Supporters have a point too. CBS News's own test found a bodega peptide product contained no peptide, which shows how unreliable the current market is, and the policy's conditions on sourcing, testing and adverse event reporting offer more oversight than online research chemical sales. Neither side has data on whether the new channel will replace the gray market or simply widen use, and supporters say less about the fact that enforcement discretion can be withdrawn at any time, leaving pharmacies without firm legal footing. Public comment closes Nov. 13, according to CBS News. AJMC reported that five more peptides go before the advisory committee in February, that HHS may revisit the policy if a safety signal appears, and that industry voices expect friction with state pharmacy regulators. Leerink's Michael Cherny told BioPharma Dive the notice falls short of the clearance telehealth firms such as Hims & Hers would need to scale up, so the FDA's eventual bulks list rule remains the decision that matters most.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

HHS lets compounding pharmacies offer six peptides the FDA has not approved

HHS will not penalize pharmacies that compound six unapproved peptides, overriding objections from FDA scientists.

Oct 29, 2026· Updated Oct 30, 2026
What's Going On
  • On Oct. 28, 2026, HHS posted an interim policy saying it will not take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax, according to CBS News and ABC News.
  • AJMC reported that the policy came from the HHS Office of the Secretary and was signed by Robert F. Kennedy Jr., not issued by the FDA.
  • The Associated Press, citing six people familiar with the matter, reported that most FDA scientific staff opposed the plan and that HHS switched to non-enforcement after FDA officials raised safety concerns about writing a regulation.
  • CBS News reported that the policy requires patient-specific prescriptions, ingredients from an FDA-registered maker, quality testing and reports of serious side effects, with public comment running through Nov. 13.
  • An FDA advisory panel recommended the six peptides in July and rejected a seventh, emideltide, which the new policy does not cover, according to BioPharma Dive.
Far Left: Public Citizen's Robert Steinbrook said Kennedy weakened the FDA by acting unilaterally, per BioPharma Dive.
Left: ABC News reported that no published clinical trials show these specific peptides are effective in humans.
Moderate: The AP reported that FDA staff had limited input but helped write the safeguards, such as sourcing from FDA-registered facilities.
Right: Reason's Elizabeth Nolan Brown argued licensed compounding beats foreign products labeled for research use only.
Far Right: No far-right outlet coverage of the final policy could be opened for this story.
✓ Common Ground
Voices on each side, from Reason's Elizabeth Nolan Brown to the CBS News team, treat the gray market in online and imported peptides as a real safety problem.
Supporters and critics alike acknowledge that clinical evidence for these six peptides is thin; even the Reason Foundation's Jeffrey A. Singer conceded the evidence for many peptides is weak.
Several accounts, including the AP and AJMC, agree the policy is a stopgap that does not settle whether the FDA will add the peptides to its bulks list.
Brown at Reason and critics such as Public Citizen both describe the move as going around the FDA's normal process, though they judge that very differently.
◆ All Sources (13)
PBS NewsHour (AP) - AP report: FDA scientists opposed the Trump administration's move to ease peptides accessAJMC - 5 Things to Know About HHS's Interim Peptide Compounding PolicyBioSpace - HHS clears compounding pharmacies to manufacture 6 unapproved peptidesBioPharma Dive - HHS to allow compounders to make 6 unapproved peptidesSTAT - HHS moves to allow compounding of some unapproved peptidesKFF Health News - People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA's Push for Medical Freedom.FOX 5 New York - HHS eases restrictions on certain unapproved peptidesCBS News - RFK Jr. to ease access to unapproved peptides, draft policy statesABC News - Some wellness peptides will become widely available, HHS saysFuturism - RFK Jr Opens the Floodgates on Experimental Peptides, Alarming ScientistsPublic Citizen - Stacked FDA Peptide Advisory Committee Delivers for RFK Jr.Reason - RFJ Jr. institutes backdoor approval of 6 peptidesReason Foundation - RFK Jr. is right to expand consumer access to peptides
Objective Deep Dive

The policy grows out of a two-year fight. In 2023 the FDA placed BPC-157, TB-500 and other peptides on a list of substances that should not be compounded, citing risks such as immune reactions, according to the AP. Kennedy, who has called himself a "big fan" of peptides according to the AP, reshaped the FDA's compounding advisory panel, which in July voted to recommend six of seven peptides under review. AJMC reported that HHS then issued enforcement discretion through the Secretary's office after FDA staff resisted writing a rule declaring the products safe.

Critics are on firm ground about the evidence: ABC News reported no published human trials show these peptides work for any condition, and FDA scientists flagged possible liver damage and allergic reactions, according to KFF Health News. Supporters have a point too. CBS News's own test found a bodega peptide product contained no peptide, which shows how unreliable the current market is, and the policy's conditions on sourcing, testing and adverse event reporting offer more oversight than online research chemical sales. Neither side has data on whether the new channel will replace the gray market or simply widen use, and supporters say less about the fact that enforcement discretion can be withdrawn at any time, leaving pharmacies without firm legal footing.

Public comment closes Nov. 13, according to CBS News. AJMC reported that five more peptides go before the advisory committee in February, that HHS may revisit the policy if a safety signal appears, and that industry voices expect friction with state pharmacy regulators. Leerink's Michael Cherny told BioPharma Dive the notice falls short of the clearance telehealth firms such as Hims & Hers would need to scale up, so the FDA's eventual bulks list rule remains the decision that matters most.

◈ Tone Comparison

Critics leaned on images of opened floodgates (Futurism) and an undermined FDA (Public Citizen's Robert Steinbrook), casting the policy as a bypass of science. Supporters adopted HHS's language of patient choice and freedom, and Reason, while backing the move, still labeled it a backdoor approval in its headline.